Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Launch New Database in 2001

SAN FRANCISCO, Jan 11 - Gene Logic will launch a new database in 2001 that will offer information about the effect pharmaceuticals have on gene expression, CEO Mark Gessler said Thursday.

" [We] will look for extremely comprehensive information on the effect of drugs on all the genes in the genome," said Gessler.

The new database, PharmExpress, will gather this information using tissue samples the company routinely collects. Gessler noted that the company is already able to gather such data by collecting information about the drugs its patients use before running tests on their tissue samples.

PharmExpress will be the company's third database. Gene Logic currently markets BioExpress, a database of gene expression information based on diseased and healthy tissue samples, and ToxExpress, which offers data on the effects of more than 10 toxic compounds on the liver, kidney, bone marrow, and heart of animals.

Eight of Gene Logic's 14 customers have subscriptions to ToxExpress, while the remaining six have subscriptions to BioExpress.

The company typically charges large pharmaceutical firms about $4 million per year for a subscription and biotechs $2 million per year. Subscriptions to subsets of the databases generally go for $1.5 million. Terms are usually for three years, Gessler said.

A spokesman for the company said that Gene Logic might also consider selling its GX2000 software separately as a way of generating an additional revenue stream. Right now the data integration software is only available with a database subscription.

The company estimates revenues of $40 million in 2001, up from an estimated $25 million for 2000.
The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.